<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216385</url>
  </required_header>
  <id_info>
    <org_study_id>ICA4-CT 2002-10057</org_study_id>
    <nct_id>NCT00216385</nct_id>
  </id_info>
  <brief_title>A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis</brief_title>
  <official_title>A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <brief_summary>
    <textblock>
      Tuberculosis is currently treated with a 6-month course regimen. During this time many
      patients might fail to adhere to treatment and default, increasing the risk of recurrent
      disease which might be multidrug resistant. A shorter duration of treatment is expected to
      provide improved patient compliance and at least equal or better clinical outcome. The aim of
      the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four
      months duration for the treatment of pulmonary tuberculosis,
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to evaluate the efficacy and safety of the 4-month test gatifloxacin-containing
      regimen, comparison will be made with a standard 6-month regimen, recommended by WHO.
      Patients will be treated with one of the two regimens that will be randomly allocated. A
      total of 2070 patients will ne recruited in the trial and followed-up for a duration of 2
      years. The trial is multicentre, and conducted in 5 countries in Africa.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date>December 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Percentage of relapses by 24 months following treatment cure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Percentage of adverse events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Time to relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of smear and culture conversion at 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of patient cured at the end of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Time to a composite “unsatisfactory” endpoint</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety outcome: Distribution of type and grading of adverse events</measure>
  </secondary_outcome>
  <enrollment>2070</enrollment>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gatifloxacin combined regimen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients

          -  Aged 18 to 65 years

          -  Currently suffering from recently diagnosed microscopically proven pulmonary
             tuberculosis and providing informed consent for inclusion in the study.

        Exclusion Criteria:

          -  Patients with history of tuberculosis treatment within the last 3 years

          -  History of diabetes mellitus or non insulin dependent diabetes mellitus requiring
             treatment

          -  Concomitant infection requiring additional anti-infective treatment (especially
             anti-retroviral therapy)

          -  HIV infected patients with WHO stage 3 infection - except those presenting with only
             the &quot;loss of weight&gt;10% body weight&quot; criterion - and all HIV infected patients at WHO
             stage 4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Lienhardt, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Programme National de Lutte contre la Tuberculose</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gninafon, MD</last_name>
      <phone>+ 229 33 15 33</phone>
      <email>pnt@intnet.bj</email>
    </contact>
    <investigator>
      <last_name>Martin Gninafon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Pneumo-Phtisiologie, CHU Ignace Deen</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oumou Y Sow, MD</last_name>
      <phone>+224 41 20 58</phone>
      <email>prsow@kassa.sotelgui.net.gn</email>
    </contact>
    <investigator>
      <last_name>Oumou Sow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Odhiambo, MD</last_name>
      <phone>+ 254 02 71 30 08</phone>
      <email>jodhiambo@nairobi.mimcom.net</email>
    </contact>
    <investigator>
      <last_name>Joseph Odhiambo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Programme National de Lutte contre la Tuberculose</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheikh Seck, MD</last_name>
      <phone>+ 221 824.90.09</phone>
      <email>cheikbaf@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Cheikh Seck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research Council</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxana Rustomjee, MD</last_name>
      <phone>+27 31 207 16 75</phone>
      <email>Roxana.rustomjee@mrc.ac.za</email>
    </contact>
    <investigator>
      <last_name>Roxana Rustomjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Guinea</country>
    <country>Kenya</country>
    <country>Senegal</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 20, 2005</last_update_submitted>
  <last_update_submitted_qc>September 20, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2005</last_update_posted>
  <keyword>Tuberculosis</keyword>
  <keyword>Treatment</keyword>
  <keyword>Quinolone</keyword>
  <keyword>Short course chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gatifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

